Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-23
2005-08-23
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06933293
ABSTRACT:
The invention relates to the use of mirtazapine for the preparation of a medicine for a new method of treatment of a sleep disorder in a subject, which treatment comprises the administration of mirtazapine with a unit treatment dose comprising between 0.1 and 5 mg mirtazapine and relates to a patient pack for the treatment of sleep disorders.
REFERENCES:
patent: 6303595 (2001-10-01), Andrews
patent: 0 813 873 (1997-12-01), None
patent: 99 25356 (1999-05-01), None
Roth et al, Clinical Cornerstone, 5(3) 2003, 5-12, abstract.
Roth et al, Sleep, 18(4) 1995, 246-251, abstract.
Czeisler, Charles A. et al.: “Disorders of Sleep and Circadian Rhythms” Harrisons Principals of Internal Medicine, 14th ed. McGraw Hill (1998) pp150-151.
Riemann, D. et al., “The Guideline for ‘Non-Restorative Sleep’: Relevance for the Diagnosis and Therapy of Insomnia”,Somnologie, 7: 66-76, 2003.
Ruigt, G.S.F., et al: “High and Low Doses of Mirtazapine Have Different Effects On Sleep”; 6thWorld Congress Biological Psychiatry NICE Jun. 22-27, 1997.
Sennef, C. et al: Effects of mirtazapine, amitriptyline and their combination on sleep in healthy volunteers measured by an ambulatory digital recording system (VITAPORT II®); 21stCINP Glasgow, Jul. 12-16, 1998.
Ruigt, G.S.F. et al: “Computer-Based Prediction of Psychotropic Drug Classes Based on a Discriminant Analysis of Drug Effects on Rat Sleep”; Neuropsychobiology 1993: 28: 138-153.
Ruigt, G.S.F.: “Sleep-Wake Research in The Netherlands”; Dutch society for sleep-wake research; vol. 6 (1995), pp 109-114.
Fawcett et al: “Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression”; Journal of Affective Disorders, 51 (1998) pp 267-285.
Fink et al: “Pharmaco-EEG Study of 6-Azamianserin (Org 3770): Dissociation of EEG and Pharmacologic Predictors of Antidepressant Activity”; Psychopharmacology, (1982) 78: 44-48.
Bremner, James D., M.D.: “A Double-Blind Comparison or Org 3770, Amitriptyline, and Placebo in Major Depression”; Journal of Clinical Psychiatry 56:11, Nov. 1995, pp 519-525.
Database Drugnl 'Online! “Organon's Mirtazapine Still Available for Licensing in the USA”, Database accession No. 92:603, Jul. 13, 1992.
E. Vester et al.: “Anxiolytic and sleep improving effects of mirtazapine in everyday clinical practice” European Neuropsychopharmacology, vol. 7, No. Suppl. 2, 1997, p. S175.
Ramaekers J G et al: “Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers.” Human Psychopharmacology, vol. 13, No. Supple. 2, Nov. 1998, pp. S87-S97.
Ruigt G S et al: “Effect of the Antidepressant Org-3770 on Human Sleep” European Journal of Clinical Pharmacology, vol. 38, No. 6, 1990, pp. 551-554.
Westenberg Herman G M: “Pharmacology of antidepressants: Selectivity of multiplicity?” Journal of Clinical Psychiatry, vol. 60, no, Suppl. 17, 1999, pp. 4-8.
Winokur Andrew et al: “Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: A pilot study.” Biological Psychiatry, vol. 48, No. 1, Jul. 1, 2000, pp. 75-78.
Thase Michael E: “Antidepressant treatment of the depressed patient with insomnia.” Journal of Clinical Psychiatry, vol. 60, No. Suppl. 17, 1999, pp. 28-31.
Sitsen J M A et al: “Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: Results from a placebo-controlled trial.” Drug Investigation, vol. 8, No. 6, 1994, pp. 339-334.
Ruigt Gerardus Stephanus Franciscus
Van den Berg Frans
Akzo Nobel N.V.
Cook Rebecca
Milstead Mark W.
LandOfFree
Use of mirtazapine for the treatment of sleep disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of mirtazapine for the treatment of sleep disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of mirtazapine for the treatment of sleep disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3523509